Demetrios Kalaitzidis, Ph.D. - Publications

2006 Boston University, Boston, MA, United States 
Molecular Biology, Cell Biology

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 McEwan B, Kuppuraju M, Padalia Z, Terrett J, Kalaitzidis D. Abstract 880: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro Immunology. 80: 880-880. DOI: 10.1158/1538-7445.Am2020-880  0.362
2020 Padalia Z, Dunn A, Karagiannis K, McEwan B, Kuppuraju M, Sagert J, Karnik S, Dequeant M, Terrett J, Kalaitzidis D. Abstract 879: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors Immunology. DOI: 10.1158/1538-7445.Am2020-879  0.335
2019 McEwan B, Padalia Z, Porras A, Sagert J, Terrett JA, Ho T, Kalaitzidis D. Abstract 1428: Allogeneic CRISPR/Cas9 gene-edited CAR-T cells targeting CD33 show potent preclinical activity against AML cells Cancer Research. 79: 1428-1428. DOI: 10.1158/1538-7445.Am2019-1428  0.385
2018 Dar H, Henderson D, Padalia Z, Porras A, Mu D, Kyungah M, Police S, Kalaitzidis D, Terrett J, Sagert J. Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma Blood. 132: 1921-1921. DOI: 10.1182/Blood-2018-99-116443  0.349
2018 Padalia Z, Porras A, Dequeant ML, Sagert J, Nguyen T, John M, Allen M, Dar H, Henderson D, Mu D, Maeng K, Huang E, Spencer S, Lorson N, Gonzales P, ... ... Kalaitzidis D, et al. Abstract 2551: Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells Cancer Research. 78: 2551-2551. DOI: 10.1158/1538-7445.Am2018-2551  0.341
2017 Lee PY, Sykes DB, Ameri S, Kalaitzidis D, Charles JF, Nelson-Maney N, Wei K, Cunin P, Morris A, Cardona AE, Root DE, Scadden DT, Nigrovic PA. The metabolic regulator mTORC1 controls terminal myeloid differentiation. Science Immunology. 2. PMID 28763796 DOI: 10.1126/Sciimmunol.Aam6641  0.422
2017 Kalaitzidis D, Lee D, Efeyan A, Kfoury Y, Nayyar N, Sykes DB, Mercier FE, Papazian A, Baryawno N, Victora GD, Neuberg D, Sabatini DM, Scadden DT. Amino acid-insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells. The Journal of Clinical Investigation. PMID 28319048 DOI: 10.1172/Jci89452  0.377
2016 Lee D, Wang YH, Kalaitzidis D, Ramachandran J, Eda H, Sykes DB, Raje N, Scadden DT. Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. The Journal of Clinical Investigation. PMID 26927669 DOI: 10.1172/Jci84620  0.42
2014 Lee D, Sykes SM, Kalaitzidis D, Lane AA, Kfoury Y, Raaijmakers MH, Wang YH, Armstrong SA, Scadden DT. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 3: 832-40. PMID 25418727 DOI: 10.1016/j.stemcr.2014.08.011  0.337
2014 Kalaitzidis D, Scadden DT. Deep diving in the blood stem cell-ome. The Embo Journal. 33: 2281-2. PMID 25190519 DOI: 10.15252/Embj.201489778  0.371
2014 Kalaitzidis D, Scadden DT. Tic-TACs: refreshing hair growth. Cell. 157: 769-70. PMID 24813602 DOI: 10.1016/J.Cell.2014.04.014  0.367
2014 Ng CE, Sinha A, Krivtsov A, Dias S, Chang J, Armstrong SA, Kalaitzidis D. KRas(G12D)-evoked leukemogenesis does not require β-catenin. Leukemia. 28: 698-702. PMID 24189294 DOI: 10.1038/Leu.2013.328  0.338
2013 Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 121: 3692-702. PMID 23487027 DOI: 10.1182/Blood-2012-05-432989  0.392
2012 Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 11: 429-39. PMID 22958934 DOI: 10.1016/j.stem.2012.06.009  0.368
2011 Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Schöll C, Tothova Z, Attar EC, et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 146: 697-708. PMID 21884932 DOI: 10.1016/J.Cell.2011.07.032  0.441
2011 Kalaitzidis D, Armstrong SA. Cancer: The flipside of Notch. Nature. 473: 159-60. PMID 21562551 DOI: 10.1038/473159A  0.408
2011 Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, et al. Erratum: AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias (Cell (2011) 146 (697-708)) Cell. 147. DOI: 10.1016/J.Cell.2011.09.015  0.398
2009 Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood. 113: 4414-24. PMID 19179468 DOI: 10.1182/blood-2008-10-182626  0.309
2008 Herscovitch M, Comb W, Ennis T, Coleman K, Yong S, Armstead B, Kalaitzidis D, Chandani S, Gilmore TD. Intermolecular disulfide bond formation in the NEMO dimer requires Cys54 and Cys347. Biochemical and Biophysical Research Communications. 367: 103-8. PMID 18164680 DOI: 10.1016/J.Bbrc.2007.12.123  0.634
2008 Chan G, Kalaitzidis D, Usenko T, Kutok J, Yang W, Mohi G, Neel B. Expression of Leukemogenic Ptpn11 Causes a Fatal Myeloproliferative Disorder by Affecting Multiple Stages of Hematopoiesis Blood. 112: 3733-3733. DOI: 10.1182/blood.v112.11.3733.3733  0.315
2007 Sullivan JC, Kalaitzidis D, Gilmore TD, Finnerty JR. Rel homology domain-containing transcription factors in the cnidarian Nematostella vectensis. Development Genes and Evolution. 217: 63-72. PMID 17120026 DOI: 10.1007/S00427-006-0111-6  0.639
2005 Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends in Endocrinology and Metabolism: Tem. 16: 46-52. PMID 15734144 DOI: 10.1016/J.Tem.2005.01.004  0.61
2004 Kalaitzidis D, Ok J, Sulak L, Starczynowski DT, Gilmore TD. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene. 23: 7580-7. PMID 15326488 DOI: 10.1038/Sj.Onc.1207912  0.693
2004 Gilmore TD, Starczynowski DT, Kalaitzidis D. RELevant gene amplification in B-cell lymphomas? Blood. 103: 3243-4; author reply. PMID 15070712 DOI: 10.1182/Blood-2003-11-4019  0.723
2004 Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 23: 2275-86. PMID 14755244 DOI: 10.1038/Sj.Onc.1207410  0.735
2003 Gilmore TD, Jean-Jacques J, Richards R, Cormier C, Kim J, Kalaitzidis D. Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines. Virology. 316: 9-16. PMID 14599786 DOI: 10.1016/S0042-6822(03)00562-2  0.596
2002 Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. Oncogene. 21: 8759-68. PMID 12483529 DOI: 10.1038/Sj.Onc.1206033  0.657
2002 Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Letters. 181: 1-9. PMID 12430173 DOI: 10.1016/S0304-3835(01)00795-9  0.721
2002 Kalaitzidis D, Gilmore TD. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes, Chromosomes & Cancer. 34: 129-35. PMID 11921291 DOI: 10.1002/Gcc.10051  0.636
Show low-probability matches.